NHIA urges commercial payers to cover COVID-19 treatment
By HME News Staff
Updated 9:18 AM CDT, Wed April 7, 2021
ALEXANDRIA, Va. – The National Home Infusion Association is urging commercial insurance plans to implement coverage policies for COVID-19 monoclonal antibody therapy used in the home. The association also says CMS’s current administration fee of approximately $310 is insufficient to cover the costs. In a study conducted in February, NHIA determined the cost of providing the therapy is between $584 and $1,746. NHIA encourages payers to work with the home infusion pharmacies in their networks to establish a fair reimbursement rate that considers the value to the plan from preventing hospitalizations and ensures providers can cover their costs.
Comments